CMB 305

Drug Profile

CMB 305

Alternative Names: CMB-305; ID-CMB305; LV 305 + G 305

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Design
  • Developer Genentech; Immune Design
  • Class Cancer vaccines; Peptide vaccines; Peptides; RNA; RNA vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I Solid tumours

Most Recent Events

  • 14 Mar 2018 Updated efficacy data from a from a phase Ib trial in Soft tissue sarcoma released by Immune Design
  • 01 Mar 2018 Immune Design plans a phase I trial for Sarcoma in USA (NCT03450122)
  • 16 Oct 2017 Immune Design plans a phase III trial for Soft tissue sarcoma (Late-stage disease, Metastatic disease, Unresectable/Inoperable, Monotherapy) in USA in mid-2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top